Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine [...]
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
NEW YORK – May 15, 2026 – Psyence BioMed Ltd. [...]
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin [...]
Psyence BioMed Positioned as World’s only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Through its investment in and collaboration with PsyLabs, the Company [...]
